There is a need for in vivo diagnostic imaging probes that can noninvasively measure tumor-
infiltrating CD8+ leukocytes. Such imaging probes could be used to predict early response …

Purpose: Noninvasive and quantitative tracking of CD8+ T cells by PET has emerged as a
potential technique to gauge response to immunotherapy. We apply an anti-CD8 cys …

CD8-expressing T cells are the main effector cells in cancer immunotherapy. Treatment-
induced changes in intratumoral CD8+ T cells may represent a biomarker to identify patients …

The rapidly advancing field of cancer immunotherapy is currently limited by the scarcity of
noninvasive and quantitative technologies capable of monitoring the presence and …

Immunotherapy is becoming the mainstay for treatment of a variety of malignancies, but only
a subset of patients responds to treatment. Tumor-infiltrating CD8-positive (CD8+) T …

The ability to non-invasively monitor tumor-infiltrating T cells in vivo could provide a powerful
tool to visualize and quantify tumor immune infiltrates. For non-invasive evaluations in vivo …

Purpose: Glioblastoma (GBM) is the most common malignant brain tumor in adults. Various
immunotherapeutic approaches to improve patient survival are being developed, but the …

Purpose: The B-cell antigen CD20 provides a target for antibody-based positron emission
tomography (immunoPET). We engineered antibody fragments targeting human CD20 and …

Purpose: The aim of this article was to evaluate the use of a novel engineered anti-CD20
protein based on the 10 kDa human fibronectin type 3 domain (FN3) and subsequently …

The CD20 cell surface antigen is expressed at high levels by over 90% of B-cell non-
Hodgkin lymphomas (NHL) and is the target of the anti-CD20 monoclonal antibody …